Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.42 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.41 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.41 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | CRHBP | P24387 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.39 |
| ▸ | GABRG2 | P18507 | 3/20 | 0.39 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | DHODH | Q02127 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1554603 | 1.00 | GPR35 (0.42) | GPR35TAS1R3TAS1R1TAS1R2TSHR | |
| SCHEMBL1553436 | 0.89 | GABRA1 (0.44) | TSHRMAPTLMNASMN1; SMN2MEN1 | |
| SCHEMBL1553437 | 0.89 | GABRA1 (0.44) | TSHRMAPTLMNASMN1; SMN2MEN1 | |
| SCHEMBL1553942 | 0.81 | GAA (0.47) | TSHRMAPTLMNASMN1; SMN2MEN1 | |
| SCHEMBL1553941 | 0.81 | GAA (0.47) | TSHRMAPTLMNASMN1; SMN2MEN1 | |
| SCHEMBL1554328 | 0.77 | SMN1; SMN2 (0.52) | TSHRMAPTLMNASMN1; SMN2MEN1 | |
| SCHEMBL1554326 | 0.77 | SMN1; SMN2 (0.52) | TSHRMAPTLMNASMN1; SMN2MEN1 | |
| SCHEMBL7548898 | 0.77 | TSHR (0.50) | GPR35TAS1R3TAS1R1TAS1R2TSHR | |
| SCHEMBL1554668 | 0.76 | MAPT (0.43) | MAPTLMNASMN1; SMN2MEN1USP2 | |
| SCHEMBL1554666 | 0.76 | MAPT (0.43) | MAPTLMNASMN1; SMN2MEN1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1383463-B1 | FUSED THIOPHENE COMPOUNDS AND USE THEREOF IN THE TREATMENT OF CHRONIC PAIN | KING PHARMACEUTICALS INC (US) | 2011-04-27 | — | — | EP | disclosed |
| EP-1383463-A4 | PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE | KING PHARMACEUTICALS INC (US) | 2009-03-25 | — | — | EP | disclosed |
| US-7449490-B2 | Pharmaceutically active compounds and methods of use | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) | 2008-11-11 | — | — | US | disclosed |
| US-7101905-B2 | Pharmaceutically active compounds and methods of use | KING PHARMACEUTICALS RESEARCH & DEVELOPMENT, INC. (US) | 2006-09-05 | — | — | US | disclosed |
| US-20060183921-A1 | Pharmaceutically active compounds and methods of use | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2006-08-17 | — | — | US | disclosed |
| EP-1383463-A2 | PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE | King Pharmaceuticals, Inc. (US) | 2004-01-28 | — | — | EP | disclosed |
| US-20030073733-A1 | Pharmaceutically active compounds and methods of use | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2003-04-17 | — | — | US | disclosed |
| WO-2002083083-A2 | PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE | KING PHARMACEUTICALS, INC. (US) | 2002-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183921-A1 | Pharmaceutically active compounds and methods of use | TRPV1, TPMT, ACHE | GPR35 517/4885TAS1R3 3480/4885TAS1R1 3864/4885 |
| US-20030073733-A1 | Pharmaceutically active compounds and methods of use | TRPV1, TPMT, ACHE | GPR35 517/4885TAS1R3 3480/4885TAS1R1 3864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.